22 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
“2013 License Agreement with Merck Serono.” We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing … , along with funding for such research; and
Table of Contents
establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare
6-K
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
, along with funding for such research; and
establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare & Medicaid Services … order on October 14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further
6-K
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
effectiveness research, along with funding for such research; and
establishment of a Center for Medicare and Medicaid Innovation at the Centers
6-K
EX-99.1
OBSVF
ObsEva SA
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
positioned to address the most challenging unmet needs facing women and bring much needed innovation to the field. I look forward to building
6-K
EX-99.1
OBSVF
ObsEva SA
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
. She is a past member of the Board of Directors of the Biotechnology Innovation Organization, the biotechnology industry association in the USA
6-K
EX-99.1
sfbyqqvcs sl
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
k8ju1o8n3km
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.1
0ek5z5xckveyi
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.2
ab7v9dp9vhhs912epg3
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
6a4qc
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.1
qy9o a95enilc2sq
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-99.2
yvhtq6oyjeumbpd8 s3
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
EX-99.1
cpio62baelgvx
30 Mar 18
Current report (foreign)
12:00am
20-F
nbdy4fcb2qfy3
21 Apr 17
Annual report (foreign)
12:00am